Onishi Hiroshi, Kuriyama Kengo, Komiyama Takafumi, Tanaka Shiho, Sano Naoki, Marino Kan, Ikenaga Satoshi, Araki Tsutomu, Uematsu Minoru
Department of Radiation Oncology, Yamanashi Medical University, 1110 Shimokato Tamaho-cho, Nakakoma-gun, Yamanashi 409-3898, Japan.
Lung Cancer. 2004 Jul;45(1):45-55. doi: 10.1016/j.lungcan.2004.01.004.
We have developed a novel irradiation technique for lung cancer that combines a linear accelerator and CT scanner with patient-controlled breath-hold and radiation beam switching. We applied this technique to stereotactic three-dimensional (3D) conformal radiotherapy for stage I non-small cell lung cancer (NSCLC) and evaluated the primary therapeutic outcomes. A total of 35 patients with stage I (15 IA, 20 IB) primary NSCLC (20 adeno, 13 squamous cell, and 2 others) were treated with this technique. Patients ranged from 65 to 92 years old (median, 78 years). Twenty-three (66%) patients were medically inoperable due to mainly chronic pulmonary disease or high age. Three-dimensional treatment plans were made using 10 different non-coplanar dynamic arcs. The total dose of 60 Gy was delivered in 10 fractions (over 5-8 days) at the minimum dose point in the planning target volume (PTV) using a 6 MV X-ray. After adjusting the isocenter of the PTV to the planned position by a unit comprising CT and linear accelerator, irradiation was performed under patient-controlled breath-hold and radiation beam switching. All patients completed the treatment course without complaint. Complete response (CR) and partial response (PR) rates were 8/35 (23%) and 25/35 (71%), respectively. Pulmonary complications of National Cancer Institute-Common Toxicity Criteria grade >2 were noted in three (9%) patients. During follow-up (range, 6-30 months; median, 13 months), two (6%) patients developed local progression and five (14%) developed distant or regional lymph node metastases. Two-year overall survival rates for total patients and medically operable patients were 58 and 83%, respectively. In conclusion, this new irradiation technique, utilizing patient-controlled radiation beam switching under self-breath-hold after precise alignment of the isocenter, allows safe high-dose stereotactic radiotherapy with sufficient margins around the CTV and reduced treatment times. Based on the initial results, excellent local control with minimal complications is expected for stage I NSCLC.
我们开发了一种用于肺癌的新型照射技术,该技术将直线加速器和CT扫描仪与患者控制的屏气及辐射束切换相结合。我们将此技术应用于I期非小细胞肺癌(NSCLC)的立体定向三维(3D)适形放疗,并评估了主要治疗结果。共有35例I期(15例IA期、20例IB期)原发性NSCLC患者(20例腺癌、13例鳞状细胞癌和2例其他类型)接受了该技术治疗。患者年龄在65至92岁之间(中位年龄78岁)。23例(66%)患者因主要是慢性肺部疾病或高龄而无法进行手术治疗。使用10种不同的非共面动态弧形进行三维治疗计划。使用6 MV X射线在计划靶体积(PTV)的最小剂量点分10次(在5 - 8天内)给予60 Gy的总剂量。通过由CT和直线加速器组成的单元将PTV的等中心调整到计划位置后,在患者控制的屏气和辐射束切换下进行照射。所有患者均顺利完成治疗过程,无不良反应。完全缓解(CR)率和部分缓解(PR)率分别为8/35(23%)和25/35(71%)。3例(9%)患者出现美国国立癌症研究所常见毒性标准>2级的肺部并发症。在随访期间(范围6 - 30个月;中位时间13个月),2例(6%)患者出现局部进展,5例(14%)患者出现远处或区域淋巴结转移。所有患者和可手术治疗患者的两年总生存率分别为58%和83%。总之,这种新的照射技术在精确对准等中心后利用患者控制的辐射束切换并在自主屏气下进行,可实现安全的高剂量立体定向放疗,在临床靶体积(CTV)周围有足够的边界并缩短治疗时间。基于初步结果,预计I期NSCLC可实现极佳的局部控制且并发症极少。